Regulation of UK aesthetic medicine has tightened steadily since the government committed to a licensing regime for non-surgical cosmetic procedures. For practitioners ordering injectables wholesale in 2026, the compliance picture matters as much as the clinical one.
MHRA and the injectable supply chain
The Medicines and Healthcare products Regulatory Agency continues to scrutinise the devices and injectable substances entering the UK market. The practical effect for clinics is twofold: traceability is now expected end-to-end, and purchasing from authorised UK distributors — rather than grey-market importers — is both safer and defensible.
Buying through a verified UK supplier means every batch number, expiry and CE/UKCA mark is documented. In an inspection or insurance claim, that paper trail is the difference between a routine review and a problem.
Licensing and the practitioner register
A national licensing scheme for non-surgical cosmetic treatments is rolling out across the UK. The direction of travel is clear: practitioners performing injectables will need to hold a licence, demonstrate prescribed qualifications, and maintain continuing professional development.
What wholesale buyers should check
- Product provenance — can your supplier evidence the UK import path?
- Storage and cold chain — were gels and boosters stored within spec?
- Batch documentation — do you receive lot numbers with every delivery?
- Insurance alignment — does your insurer accept the products you use?
The Revive Pharma position
Revive Pharma stocks only authorised, traceable product — Aessoa, Re:Prima, Teosyal, Juvederm, Restylane and more — with full batch documentation on every wholesale order. For practitioners building a defensible, future-proof clinic, that traceability is no longer optional.
